Research programme: eye-disorder therapeutics - Azura Opthalmics

Drug Profile

Research programme: eye-disorder therapeutics - Azura Opthalmics

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Azura Ophthalmics
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Meibomianitis

Most Recent Events

  • 10 Oct 2017 Clinical trials in Meibomianitis (Ophthalmic)
  • 10 Oct 2017 Azura Ophthalmics plans a phase IIa trial for Meibomianitis (Opthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top